Gross Margin % is calculated as gross profit divided by its revenue. OncoCyte's Gross Profit for the
three
months ended in Dec. 2023 was $-0.12 Mil. OncoCyte's Revenue for the
three
months ended in Dec. 2023 was $0.31 Mil. Therefore, OncoCyte's Gross Margin % for the quarter that ended in Dec. 2023 was -37.26%.
The historical rank and industry rank for OncoCyte's Gross Margin % or its related term are showing as below:
OCX'
s Gross Margin % Range Over the Past 10 Years
Min: -52.55 Med: 12.8 Max: 64.6
Current: 27.48
During the past 11 years, the highestGross Margin % of OncoCyte was 64.60%. The lowest was -52.55%. And the median was 12.80%.
OCX's Gross Margin % is ranked worse than 81.02% of 216
companies
in the Medical Diagnostics & Research industry
Industry Median: 45.595
vs OCX: 27.48
OncoCyte had a gross margin of -37.26% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for OncoCyte was 0.00% per year.
OncoCyte Gross Margin % Historical Data
The historical data trend for OncoCyte's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of OncoCyte's Gross Margin %
For the Diagnostics & Research subindustry, OncoCyte's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoCyte's Gross Margin % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's Gross Margin % distribution charts can be found below:
* The bar in red indicates where OncoCyte's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
OncoCyte (NAS:OCX) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
OncoCyte had a gross margin of -37.26% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
OncoCyte Gross Margin % Related Terms
Thank you for viewing the detailed overview of OncoCyte's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OCX has been successfully added to your 